Cytokinetics

Cytokinetics Profit per Employee

The Profit per Employee of Cytokinetics (CYTK) as of Nov 19, 2026 is -1.17 M USD. In the previous year, Profit per Employee was -875,967.31 USD — a change of 33.15% (lower).

Profit per Employee

-1.17 MUSD

YoY

33.15%

Last updated:

Profit per Employee of Cytokinetics is 2025 -1.17 M USD. Profit per Employee of Cytokinetics was 2024 -875,967.31 USD. It decreases by 33.15% lower compared to the previous year.

The Cytokinetics Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-157,933.14 USD
Jan 1, 2019
-180,820.21 USD
Jan 1, 2020
-189,138.19 USD
Jan 1, 2021
-319,931.65 USD
Jan 1, 2022
-577,942.05 USD
Jan 1, 2023
-781,937.59 USD
Jan 1, 2024
-875,967.31 USD
Jan 1, 2025
-1.17 M USD
The Cytokinetics Profit per Employee history
YEARProfit per EmployeeYoY
-1.17 MUSD+33.15%
-875,967.31USD+12.03%
-781,937.59USD+35.30%
-577,942.05USD+80.65%
-319,931.65USD+69.15%
-189,138.19USD+4.60%
-180,820.21USD+14.49%
-157,933.14USD-16.83%
-189,881.13USD-876.70%
24,447.25USD-143.87%
-55,722.14USD+156.05%
-21,762.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

Profit per Employee of Cytokinetics is -1.17 M USD in 2025.

Profit per Employee of Cytokinetics changed from -875,967.31 USD to -1.17 M USD, representing a 33.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Cytokinetics since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Cytokinetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cytokinetics

All Key Metrics — Cytokinetics